COMMENTARY

Epigenetic Drug Discovery Efforts Expanding, with Solid Cancers Now Being Targeted

September 1, 2017
By Shinya Sato Targets for epigenetic drug discovery are now expanding beyond the field of hematologic cancer. Drug makers worldwide are starting to develop epigenetic drugs for solid tumors as well. In the future, development could expand to include diseases…

To read the full story

COMMENTARY

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

The Japanese cost-effectiveness assessment (CEA) scheme should be applied not only to the price adjustments of drugs and medical devices…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…

By Tatsuya Otsuka

Driven by changes surrounding the Japanese generic drug market, generic companies are trying to shift from a “generic” to a “specialty” model for their main business, with more and more players steering their focus towards specialized areas to secure profits.The…

By Yoshinori Sagehashi

It’s official. Japan has decided to move ahead with the introduction of a cost-effectiveness assessment (CEA) scheme in April. But people from all walks of life – industry, government officials and academics included - are wondering, “What about the cost…